Faslodex is neither chemotherapy nor immunotherapy. It is a hormone therapy, specifically an estrogen receptor antagonist that treats hormone receptor-positive breast cancer by blocking and destroying estrogen receptors on cancer cells. This puts it in a completely different drug category from both chemotherapy (which kills rapidly dividing cells) and immunotherapy (which activates the immune system to fight cancer).
How Faslodex Actually Works
Faslodex (the brand name for fulvestrant) belongs to a class of drugs called selective estrogen receptor degraders, or SERDs. Some breast cancers depend on the hormone estrogen to grow. These are called estrogen receptor-positive (ER-positive) cancers, and they have receptor proteins on their surface that grab onto estrogen like a lock fitting a key. Faslodex works by binding to those receptors, blocking estrogen from attaching, and then causing the receptor itself to break down and disappear from the cell.
This is a more aggressive approach than older hormone therapies like tamoxifen, which block estrogen receptors but leave them intact. Tamoxifen can also act like a weak version of estrogen in certain tissues, which sometimes limits its effectiveness. Faslodex has no estrogen-like activity in any tissue. Once it binds to the receptor, the receptor changes shape in a way that makes it unstable, and the cell’s own recycling machinery breaks it down. Without functioning estrogen receptors, the cancer cell loses its growth signal.
Why It’s Not Chemotherapy
Chemotherapy drugs are cytotoxic, meaning they work by poisoning or damaging cells that divide rapidly. That’s why chemotherapy causes side effects like hair loss, severe nausea, and immune suppression: it doesn’t distinguish well between fast-growing cancer cells and fast-growing healthy cells in your hair follicles, gut lining, and bone marrow.
Faslodex takes an entirely different approach. It doesn’t attack cell division at all. It targets a specific hormone signaling pathway that only matters in cancers driven by estrogen. Because of this, it’s generally better tolerated than chemotherapy. Notably, hair loss is not listed among its side effects. In clinical practice, doctors often use hormone therapies like Faslodex sequentially, one after another, to delay the point where a patient needs to move to chemotherapy.
The most common side effects of Faslodex reflect its hormonal mechanism rather than the widespread cell damage seen with chemo. Injection site reactions are common (the drug is given as two intramuscular shots in the buttocks), along with joint pain, hot flashes, fatigue, and nausea. These overlap more with menopause symptoms than with the side effect profile of cytotoxic chemotherapy.
Why It’s Not Immunotherapy
Immunotherapy drugs work by stimulating or unleashing your immune system to recognize and attack cancer cells. The most well-known types are checkpoint inhibitors, which remove the “brakes” that cancer cells put on immune responses. Faslodex does nothing to the immune system. It works entirely through hormone receptor biology, starving cancer cells of the estrogen signal they need to proliferate. There is no immune activation, no checkpoint inhibition, and no interaction with T cells or other immune components in its mechanism of action.
Who Faslodex Is Prescribed For
The FDA has approved Faslodex for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. It can be used in three main scenarios: as a first-line treatment for patients who haven’t yet received any hormone therapy, as a second-line option after another hormone therapy has stopped working, or in combination with a class of targeted drugs called CDK4/6 inhibitors after disease progression on prior endocrine therapy.
The combination with CDK4/6 inhibitors has become a cornerstone of treatment for advanced hormone-positive breast cancer. Several CDK4/6 inhibitors are approved for use alongside Faslodex, and all of them significantly improve the time before the cancer progresses. This combination is also used for patients who can’t tolerate aromatase inhibitors (another type of hormone therapy) due to side effects like severe bone loss.
What Treatment Looks Like
Faslodex is given as a 500 mg injection, split into two shots (one in each buttock), administered slowly over one to two minutes per injection. The schedule starts with injections on day 1, day 15, and day 29, then continues once monthly after that. Unlike chemotherapy infusions that may take hours in a clinic, these injections are relatively quick, though the intramuscular shots can be uncomfortable.
Because Faslodex is a hormone therapy and not chemotherapy, it doesn’t require the same pre-medications, recovery time, or intensive monitoring that chemo cycles typically involve. Most patients continue their normal daily activities between appointments. Treatment continues as long as the cancer responds and the side effects remain manageable.